

Leo Mascarenhas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336231/publications.pdf>

Version: 2024-02-01

123
papers

6,637
citations

172457
29
h-index

66911
78
g-index

125
all docs

125
docs citations

125
times ranked

8489
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Larotrectinib in <i>TRK</i> Fusion-Positive Cancers in Adults and Children. <i>New England Journal of Medicine</i> , 2018, 378, 731-739.	27.0	2,036
2	Larotrectinib in patients with <i>TRK</i> fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	10.7	608
3	Larotrectinib for paediatric solid tumours harbouring <i>NTRK</i> gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2018, 19, 705-714.	10.7	419
4	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1396-1408.	10.7	356
5	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. <i>European Journal of Cancer</i> , 2019, 109, 36-50.	2.8	354
6	Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2094-2101.	1.6	269
7	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1424-1431.	1.6	172
8	Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2008, 51, 334-338.	1.5	164
9	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2770-2777.	1.6	124
10	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 287.	7.1	114
11	Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. <i>Blood</i> , 2000, 96, 1317-1326.	1.4	100
12	The use of neoadjuvant larotrectinib in the management of children with locally advanced <i>TRK</i> fusion sarcomas. <i>Cancer</i> , 2018, 124, 4241-4247.	4.1	100
13	Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4658-4663.	1.6	92
14	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. <i>British Journal of Cancer</i> , 2018, 119, 615-621.	6.4	83
15	Randomized Phase II Trial of Bevacizumab or Temezirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2866-2874.	1.6	70
16	Sarcomas. <i>Pediatric Clinics of North America</i> , 2015, 62, 179-200.	1.8	65
17	Extracranial malignant rhabdoid tumors in childhood. <i>Cancer</i> , 2007, 110, 2061-2066.	4.1	64
18	Screening for Cardiac Dysfunction in Anthracycline-Exposed Childhood Cancer Survivors. <i>Clinical Cancer Research</i> , 2014, 20, 6314-6323.	7.0	61

#	ARTICLE	IF	CITATIONS
19	Expanding the spectrum of dicer1-associated sarcomas. <i>Modern Pathology</i> , 2020, 33, 164-174.	5.5	57
20	Extended mutational analyses of FGFR1 in osteoglyphonic dysplasia. <i>American Journal of Medical Genetics, Part A</i> , 2006, 140A, 537-539.	1.2	45
21	Effect of Time to Resumption of Chemotherapy After Definitive Surgery on Prognosis for Non-Metastatic Osteosarcoma. <i>Journal of Bone and Joint Surgery - Series A</i> , 2009, 91, 604-612.	3.0	43
22	Gorham's disease and diffuse lymphangiomatosis in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2011, 56, 667-670.	1.5	41
23	A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors. <i>PLoS ONE</i> , 2013, 8, e68416.	2.5	41
24	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. <i>Journal of Clinical Oncology</i> , 2021, 39, 4029-4038.	1.6	41
25	Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2011, 57, 939-942.	1.5	36
26	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 1998, 92, 3537-3545.	1.4	34
27	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017, 129, 1919-1926.	1.4	32
28	Inflammatory Myofibroblastic Tumors in Childhood. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 640-645.	0.8	30
29	Pulmonary function abnormalities in childhood cancer survivors treated with bleomycin. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1679-1684.	1.5	30
30	Vincristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26728.	1.5	30
31	Relapsed Rhabdomyosarcoma. <i>Journal of Clinical Medicine</i> , 2021, 10, 804.	2.4	30
32	Tumor necrosis predicts survival following neoadjuvant chemotherapy for hepatoblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 493-498.	1.5	28
33	High dose alkylator therapy for extracranial malignant rhabdoid tumors in children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1357-1361.	1.5	27
34	Inherited germline <i>ATR</i> mutation in two brothers with <i>ATR</i> syndrome and osteosarcoma. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1390-1395.	1.2	27
35	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017, 35, 1730-1736.	1.6	26
36	Randomized phase II trial of bevacizumab and temsirolimus in combination with vinorelbine (V) and cyclophosphamide (C) for first relapse/disease progression of rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10003-10003.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Correlation of Clinical and Dosimetric Factors With Adverse Pulmonary Outcomes in Children After Lung Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 942-948.	0.8	24
38	Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. <i>Pediatric Blood and Cancer</i> , 2014, 61, 756-759.	1.5	24
39	Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 493-498.	1.5	23
40	Treatment of infantile choriocarcinoma of the liver. <i>Pediatric Blood and Cancer</i> , 2007, 49, 99-102.	1.5	22
41	Evaluation of persistent pulmonary infiltrates in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2007, 48, 165-172.	1.5	22
42	Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2019, 125, 2602-2609.	4.1	21
43	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. <i>Cancer</i> , 2021, 127, 1301-1310.	4.1	20
44	Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1277-1281.	1.5	19
45	Hepatoblastoma in a patient with methylmalonic aciduria. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 635-638.	1.2	19
46	Hepatocellular malignant neoplasm, <scp>NOS</scp>: a clinicopathological study of 11 cases from a single institution. <i>Histopathology</i> , 2017, 71, 813-822.	2.9	19
47	Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia. <i>JAMA Network Open</i> , 2020, 3, e2014205.	5.9	19
48	Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10004-10004.	1.6	19
49	Zoledronic Acid for the Treatment of Children With Refractory Central Giant Cell Granuloma. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e399-e401.	0.6	18
50	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 41-50.	2.3	18
51	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 785-796.	1.2	18
52	Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Cancer</i> , 2021, 127, 946-956.	4.1	18
53	Metabolic response as assessed by ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. <i>Cancer Medicine</i> . 2021, 10, 857-866.	2.8	18
54	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29644.	1.5	18

#	ARTICLE	IF	CITATIONS
55	Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1109-1114.	2.5	17
56	Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. <i>Sarcoma</i> , 2020, 2020, 1-6.	1.3	17
57	Gene Delivery to Human B-Precursor Acute Lymphoblastic Leukemia Cells. <i>Blood</i> , 1998, 92, 3537-3545.	1.4	15
58	Pleuropulmonary Blastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e182-e185.	0.6	14
59	Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. <i>Cancer Medicine</i> , 2016, 5, 294-303.	2.8	14
60	Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3688-3696.	1.6	14
61	Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10010-10010.	1.6	14
62	A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1103-1107.	1.5	13
63	De Novo Congenital Melanoma. <i>American Journal of Dermatopathology</i> , 2014, 36, 915-919.	0.6	13
64	Nuclear Protein in Testis Midline Carcinoma Misdiagnosed As Adamantinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e57-e60.	1.6	13
65	Is INI1-retained small cell undifferentiated histology in hepatoblastoma unfavorable?. <i>Human Pathology</i> , 2015, 46, 620-624.	2.0	13
66	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARCO24 Study. <i>Oncologist</i> , 2020, 25, e1655-e1662.	3.7	13
67	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28832.	1.5	13
68	Severe Methotrexate Toxicity Precipitated by Intravenous Radiographic Contrast. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 496-499.	0.6	12
69	Abnormal Pulmonary Lymphatic Flow in Patients With Lymphatic Anomalies and Respiratory Compromise. <i>Chest</i> , 2020, 158, 681-691.	0.8	11
70	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. <i>Journal of Clinical Medicine</i> , 2021, 10, 1416.	2.4	11
71	A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10510-10510.	1.6	11
72	Invasive diagnostic procedures for pulmonary infiltrates in pediatric hematopoietic stem cell transplant recipients. <i>Pediatric Transplantation</i> , 2007, 11, 736-742.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 26-31.	0.8	9
74	Three synchronous malignancies in a patient with DICER1 syndrome. <i>European Journal of Cancer</i> , 2018, 93, 140-143.	2.8	9
75	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	2.0	9
76	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10549-10549.	1.6	9
77	Transient myeloproliferative disorder in a phenotypically normal infant with i(21q) mosaicism. <i>Cancer Genetics and Cytogenetics</i> , 2002, 136, 138-140.	1.0	8
78	Correlation of pulmonary function abnormalities with dose volume histograms in children treated with lung irradiation. <i>Pediatric Pulmonology</i> , 2015, 50, 596-603.	2.0	8
79	Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11514-11514.	1.6	7
80	Kaposiform hemangioendothelioma of the bone in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29392.	1.5	7
81	Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis. <i>JAMA Network Open</i> , 2022, 5, e2148013.	5.9	7
82	Hepatoblastoma in a 15-month-old female with trisomy 13. <i>American Journal of Medical Genetics, Part A</i> , 2014, 164, 472-475.	1.2	6
83	Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10009-10009.	1.6	6
84	Hepatoblastoma and hypoplastic kidneys: A new association. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1476-1478.	1.5	5
85	Pilot Feasibility Study of Comprehensive Pulmonary Evaluation Following Lung Radiation Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e412-e418.	0.6	5
86	Cutaneous mosaic RASopathies associated with rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29639.	1.5	5
87	Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 61-63.	1.3	4
88	Successful Treatment of Recurrent Metastatic Nasopharyngeal Carcinoma With Oxaliplatin and Doxorubicin. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e307-e309.	0.6	4
89	Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 480-485.	1.0	4
90	A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL): A COG ACCL1033 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10007-10007.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.. Journal of Clinical Oncology, 2022, 40, 10030-10030.	1.6	4
92	Recurrent and Refractory Giant Cell Tumor of the Jaw. Journal of Craniofacial Surgery, 2009, 20, 2245-2248.	0.7	3
93	Ewing sarcoma of the tibia mimicking fibrous dysplasia. Journal of Pediatric Orthopaedics Part B, 2013, 22, 222-227.	0.6	3
94	Insulin-like Growth Factor 2 Gene Expression Molecularly Differentiates Pleuropulmonary Blastoma and Embryonal Rhabdomyosarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e356-e360.	0.6	3
95	Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine, 2021, 10, 843-856.	2.8	3
96	A pediatric phase 1 study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.. Journal of Clinical Oncology, 2016, 34, TPS10583-TPS10583.	1.6	3
97	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. Journal of Clinical Oncology, 2018, 36, 11505-11505.	1.6	3
98	Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.. Journal of Clinical Oncology, 2019, 37, 6602-6602.	1.6	3
99	Pediatric Metastatic Hepatoblastoma With an <i>ARID1A</i> Mutation and Rhabdoid Cells. International Journal of Surgical Pathology, 2022, 30, 307-312.	0.8	2
100	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1). Blood, 2012, 120, 882-882.	1.4	2
101	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	1.6	2
102	A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with <i>RET</i> -altered cancers.. Journal of Clinical Oncology, 2019, 37, TPS10066-TPS10066.	1.6	2
103	Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.. Journal of Clinical Oncology, 2020, 38, 3614-3614.	1.6	2
104	Results of a phase I trial of ganitumab plus dasatinib in patients with rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2022, 40, 11561-11561.	1.6	2
105	Correlation of long-term pulmonary injury with radiation dose distribution in childhood cancer survivors. Practical Radiation Oncology, 2012, 2, 237-240.	2.1	1
106	Orthopaedic Case of the Month: A 14-Year-Old Boy With a Medial Thigh Soft Tissue Mass. Clinical Orthopaedics and Related Research, 2013, 471, 1433-1438.	1.5	1
107	Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.. Journal of Clinical Oncology, 2021, 39, TPS11577-TPS11577.	1.6	1
108	A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. Journal of Clinical Oncology, 2013, 31, TPS10591-TPS10591.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.. Journal of Clinical Oncology, 2017, 35, TPS10577-TPS10577.	1.6	1
110	Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.. Journal of Clinical Oncology, 2018, 36, 10541-10541.	1.6	1
111	Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer andNTRKgene fusions or other alterations. , 2020, , .		1
112	ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.. Journal of Clinical Oncology, 2022, 40, TPS11591-TPS11591.	1.6	1
113	Phase 1 clinical trial of durvalumab in children with solid and central nervous system tumors.. Journal of Clinical Oncology, 2022, 40, 10029-10029.	1.6	1
114	A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma. Journal of Clinical Oncology, 2021, 39, 2851-2854.	1.6	0
115	Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma.. Journal of Clinical Oncology, 2012, 30, 9564-9564.	1.6	0
116	Comprehensive profiling of cardiac dysfunction in asymptomatic childhood cancer survivors (CCS) treated with anthracyclines.. Journal of Clinical Oncology, 2013, 31, 10020-10020.	1.6	0
117	Combined clinical and genetic risk prediction of central nervous system subsequent neoplasms (CNS) Tj ETQq1 1 0.784314 rgBT /Ove Oncology, 2016, 34, 10511-10511.	1.6	0
118	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. Journal of Clinical Oncology, 2017, 35, 10514-10514.	1.6	0
119	A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS2599-TPS2599.	1.6	0
120	Abstract PR07: A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: An updated analysis. , 2018, , .		0
121	Abstract CT109: A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma. , 2019, , .		0
122	Reply to J.-G. Wang et al. Journal of Clinical Oncology, 2022, , JCO2102922.	1.6	0
123	Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation.. Journal of Clinical Oncology, 2022, 40, 10042-10042.	1.6	0